Lieke H. van der Helm

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme

Lieke H. van der Helm, Canan Alhan, Pierre W. Wijermans et al. · British Journal of Haematology · 2011 · 106 citations · Full text

Medicine, Hematology, Pharmacology +11

Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients

Lieke H. van der Helm, Ellen R. M. Scheepers, Nic J.G.M. Veeger et al. · Journal of Hematology & Oncology · 2013 · 52 citations · Full text

Medicine, Oncology, Pharmacology +11

Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts

Lieke H. van der Helm, Nic J.G.M. Veeger, Marinus van Marwijk Kooy et al. · Leukemia Research · 2013 · 34 citations · Full text

Medicine, Hematology, Pharmacology +15

Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes

Canan Alhan, Theresia M. Westers, Lieke H. van der Helm et al. · Cytometry Part B Clinical Cytometry · 2014 · 33 citations

Medicine, Hematology, Oncology +14

Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes

Canan Alhan, Theresia M. Westers, Lieke H. van der Helm et al. · Cytometry Part B Clinical Cytometry · 2014 · 19 citations

Medicine, Hematology, Oncology +14